The company's lead product candidate, GC4419, is a small molecule dismutase mimetic that reduces the incidence and duration of radiation-induced severe oral mucositis in patients with head and neck cancer. GC4419 has received Fast Track and Breakthrough Therapy designations from the U.S. Food and Drug Administration. Galera Therapeutics is focused on developing and commercializing a pipeline of proprietary therapeutics that have the potential to transform radiotherapy in cancer.